About: BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) may exacerbate COVID-19 and worsen associated outcomes by upregulating the enzyme that SARS-CoV-2 binds to enter cells. However, to our knowledge, no study has examined the association between NSAID use and the risk of COVID-19-related outcomes among hospitalised patients. METHODS: We conducted a population-based cohort study using South Korea nationwide healthcare database, which contains data of all subjects who received a test for COVID-19 (n=69,793) as of April 8, 2020. We identified a cohort of adults hospitalised with COVID-19, where cohort entry was the date of hospitalisation. NSAIDs users were those prescribed NSAIDs while hospitalised and non-users were those not prescribed NSAIDs. Our primary outcome was a composite of death, intensive care unit admission, mechanical ventilation use, and sepsis; secondary outcome was cardiovascular or renal complications. We conducted logistic regression analysis to estimate adjusted odds ratio (aOR) with 95% confidence intervals (CI) for the risk of these outcomes associated with NSAIDs users versus non-users, using propensity score-inverse probability of treatment weighting to minimize potential confounding. In sensitivity analyses, we compared NSAIDs to paracetamol (acetaminophen) to minimize confounding by indication. FINDINGS: Of 1,824 adults hospitalised with COVID-19 (mean age 44.7 years; female 59%), 285 were NSAIDs users and 1,539 were non-users. Compared with non-users, NSAIDs users were associated with increased risks of the primary composite outcome (aOR 1.54, 95% CI 1.11-2.15) and cardiovascular or renal complications (aOR 2.64, 95% CI 1.67-4.16). The association with primary outcome remained consistent when comparing NSAIDs to paracetamol (aOR 1.31, 95% CI 0.89-1.95). INTERPRETATION: Use of NSAIDs, compared with non-use, is associated with worse outcomes among hospitalised COVID-19 patients. While awaiting the results of confirmatory studies, we suggest NSAIDs be used with caution as the harms associated with their use may outweigh their benefits in this population.   Goto Sponge  NotDistinct  Permalink

An Entity of Type : fabio:Abstract, within Data Space : wasabi.inria.fr associated with source document(s)

AttributesValues
type
value
  • BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) may exacerbate COVID-19 and worsen associated outcomes by upregulating the enzyme that SARS-CoV-2 binds to enter cells. However, to our knowledge, no study has examined the association between NSAID use and the risk of COVID-19-related outcomes among hospitalised patients. METHODS: We conducted a population-based cohort study using South Korea nationwide healthcare database, which contains data of all subjects who received a test for COVID-19 (n=69,793) as of April 8, 2020. We identified a cohort of adults hospitalised with COVID-19, where cohort entry was the date of hospitalisation. NSAIDs users were those prescribed NSAIDs while hospitalised and non-users were those not prescribed NSAIDs. Our primary outcome was a composite of death, intensive care unit admission, mechanical ventilation use, and sepsis; secondary outcome was cardiovascular or renal complications. We conducted logistic regression analysis to estimate adjusted odds ratio (aOR) with 95% confidence intervals (CI) for the risk of these outcomes associated with NSAIDs users versus non-users, using propensity score-inverse probability of treatment weighting to minimize potential confounding. In sensitivity analyses, we compared NSAIDs to paracetamol (acetaminophen) to minimize confounding by indication. FINDINGS: Of 1,824 adults hospitalised with COVID-19 (mean age 44.7 years; female 59%), 285 were NSAIDs users and 1,539 were non-users. Compared with non-users, NSAIDs users were associated with increased risks of the primary composite outcome (aOR 1.54, 95% CI 1.11-2.15) and cardiovascular or renal complications (aOR 2.64, 95% CI 1.67-4.16). The association with primary outcome remained consistent when comparing NSAIDs to paracetamol (aOR 1.31, 95% CI 0.89-1.95). INTERPRETATION: Use of NSAIDs, compared with non-use, is associated with worse outcomes among hospitalised COVID-19 patients. While awaiting the results of confirmatory studies, we suggest NSAIDs be used with caution as the harms associated with their use may outweigh their benefits in this population.
subject
  • Zoonoses
  • Viral respiratory tract infections
  • COVID-19
  • Hepatotoxins
  • Nonsteroidal anti-inflammatory drugs
  • Occupational safety and health
  • Chiroptera-borne diseases
part of
is abstract of
is hasSource of
Faceted Search & Find service v1.13.91 as of Mar 24 2020


Alternative Linked Data Documents: Sponger | ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software